GRTS / Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might d more_horizontal

GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 studies. GRTS has secured a $433 more_horizontal

Gritstone bio, Inc. (NASDAQ:GRTS ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 AM ET Company Participants George MacDougall - Director, Investo more_horizontal

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to l more_horizontal

Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point. more_horizontal

Gritstone bio Inc. (NASDAQ:GRTS ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants George MacDougall - Director, Investo more_horizontal

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numb more_horizontal

EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop th more_horizontal